RNXTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
RenovoRx, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.16+0.02 (+1.75%)
Close on Oct 19, 2026
- Market cap
- $54.87M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.04 (+3.57%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
RenovoRx, Inc. reported revenue of $1.98M for the twelve months to Jun 30, 2026. Free cash flow was -$11.94M.
Revenue
$1.98M
TTM Q2 2026
Operating income
-$13.54M
TTM Q2 2026
Free cash flow
-$11.94M
TTM Q2 2026
EPS, diluted
-$0.31
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $54.87M
- P/E ratio
- –
- Price to sales
- 27.77
- Price to book
- 6.11
- Dividend yield
- –
- Free cash flow yield
- -21.76%
Fundamentals
- Revenue
- $1.98M
- Net income
- -$12.29M
- EPS, diluted
- -$0.31
- Free cash flow
- -$11.94M
- Book value per share
- $0.19
- Diluted shares
- 47M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$1.98M
Gross profit
$1.67M
Operating income
-$13.54M
Net income
-$12.29M
EPS, diluted
-$0.31
Free cash flow
-$11.94M
Reported periodTrailing twelve months